Cambridge Healthtech Institute’s 3rd Annual

PROTACs and Targeted Protein Degradation

Part 1: Molecular Glues, Chimeras and Covalent Inhibitors as Novel Degraders

September 28-29, 2021

Part 2: Proteomic Assays and Screening Strategies for Identifying Degradation Targets

September 29-30, 2021

 

The ubiquitin-proteasome system (UPS) and the autophagy-lysosome system are responsible for protein degradation and maintenance of proteostasis. They consist of well-controlled, selective mechanisms for intracellular protein degradation, however, the diversity and complexity makes it difficult to target these pathways for therapeutic intervention. Better understanding of ways to modulate these pathways using chemical probes, small molecule ligands and innovative screening platforms have made some UPS and autophagy targets more "druggable". Cambridge Healthtech Institute’s conference on PROTACs and Targeted Protein Degradation will bring together chemists, biologists and pharmacologists to discuss the progress that has been made and the challenges that are yet to be overcome.

 

Who should attend: Scientists in Molecular and Cellular Biology, Discovery Biology, Target Discovery, Medicinal Chemistry, Discovery Chemistry, Lead Discovery, DMPK, Pharmacology, Target Identification and Validation, Chemical Biology, Proteomics, Assay Development, and Molecular Screening

 

Part 1:

The UPS and autophagy pathways act as key regulators in cancer, CNS and other diseases. The first part of the PROTACs and Targeted Protein Degradation conference will discuss ways to design and optimize small molecule degraders such as, proteolysis-targeting chimeras (PROTACs), E3 ligase and deubiquitinating enzyme (DUB) modulators, thalidomides and other molecular glues. Challenges that exist in terms of stability, biodistribution and penetration of these molecules for better in vitro to in vivo translation will be discussed.

 

Coverage will include, but is not limited to:

 

  • Designing and optimizing PROTACs for tackling undruggable targets
  • Exploring chemically diverse small molecules for targeted protein degradation
  • Developing new probes and modulators of chaperones, DUBs, E2 and E3 ligases for targeting the UPS
  • Development of macrocyclic and peptide-based PROTACs
  • Use of new linkers and binders like nanobodies, antibodies and more
  • Optimizing pharmacokinetic properties: specificity, stability, penetration and biodistribution

 

Part 2:

The UPS and autophagy pathways hold a lot of promise in seeking out previously “undruggable” targets for therapeutic intervention. The second part of the PROTACs and Targeted Protein Degradation conference will focus on emerging assays and screening strategies for identifying ligases, chaperone proteins, DUBs and other proteins that can be modulated for targeted protein degradation.

 

Coverage will include, but is not limited to:

 

  • Emerging tools and assays to simulate, probe and quantify the autophagy/ubiquitin pathways
  • Identifying novel ligases, DUBs and chaperones proteins for hijacking the UPS
  • Understanding the role of UPS/autophagy in oncology, CNS, autoimmune, metabolic and infectious diseases
  • Exploiting the interplay between autophagy, ubiquitin and other cellular responses
  • Using degradation to pursue "undruggable" targets: KRAS, transcription factors and more
  • Finding new approaches for protein degradation 

 

If you would like to submit a proposal to give a presentation at this meeting, please click here.

 

The deadline for priority consideration is March 19, 2021.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

For more details on the conference, please contact:

Tanuja Koppal, PhD

Senior Conference Director

Cambridge Healthtech Institute

Email: tkoppal@healthtech.com

 

For partnering and sponsorship information, please contact:

Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286

Email: reymael@healthtech.com


Please click here to continue to the agenda for PROTACs and Targeted Protein Degradation - Part 2


Submit a Speaker Proposal